The Castleman Disease Treatment Market was valued at approximately USD 600 million in 2025 and is projected to reach around USD 1 billion by 2035, expanding at a CAGR of approximately 4.4% from 2026 to 2035. Increasing awareness of Castleman disease, advances in therapeutic approaches, and greater investment in rare-disease research are supporting the development of the treatment landscape.
Monoclonal antibodies represent an important treatment category and are gaining traction because of their targeted approach. The segment was valued at approximately USD 250 million in 2024 and is projected to reach about USD 450 million by 2035.
Corticosteroids remain relevant for managing inflammation and disease-related symptoms. Chemotherapy and interferon therapy are also used in selected treatment approaches, while antiviral therapy can have an important role for specific patient populations.
Intravenous administration is expected to maintain a leading position because it can provide direct delivery of therapeutic agents. Subcutaneous and oral administration routes are also creating opportunities for more convenient treatment options.
Advances in genomic research and personalized medicine are influencing the development of Castleman disease therapies. Better understanding of individual disease characteristics can support more targeted treatment strategies.
As awareness, diagnosis, research investment, and therapeutic innovation continue to increase, the Castleman Disease Treatment Market is expected to expand steadily through 2035.
